Inositol and FSH: A new frontier for the androgenetic alopecia tr | 16995
Endocrinology & Metabolic Syndrome

Endocrinology & Metabolic Syndrome
Open Access

ISSN: 2161-1017

+44 7868 792050

Inositol and FSH: A new frontier for the androgenetic alopecia treatment in PCOS

Polycystic Ovarian Syndrome Conference

November 16-18, 2015 Seattle, USA

Giuseppe Gullo

University of Palermo cum laude, Italy

Posters-Accepted Abstracts: Endocrinol Metab Syndr

Abstract :

Context: Many papers demonstrated the inositol effects in terms of better insulin sensitivity, ovulatory function, androgen levels reductions; FSH ovarian response and on the metabolic pattern. Objective: To evaluate the therapeutic effect of the insulin sensitizing integration on the androgenetic alopecia (AA) Methods: Exclusion criteria: Use of hormonal medications including oral contraceptives or insulin-sensitizing in the previous six months. Inclusion criteria: Hyper androgenism with skin symptoms. AA rated according to Ludwig scale, hirsutism rated with F.G. score modified (Hatch), acne based on the face, chest and back injuries number. Patients: Longitudinal observational study on 10-30 pts. Interventions: BMI>25: MYO 550 mg+DCI 13.8 mg (ratio 40/1) plus folic acid 200 mg, soft gel caps twice daily. BMI<25: MYO 2 gr plus folic acid 200 mg, soluble powder twice daily. Plasma levels, clinical signs and self- patientsâ?? assessment were recorded at three and six months of treatment. Main outcome measures: 20-70% hair loss reduction without side effects. Results: Significant reduction in BMI/HC, PCOS and cutaneous hyperandrogenism signs almost all in resolution. Conclusions: Previously our results support the hypothesis about inositol as second FSH messenger. The treatment demonstrated an androgen and their peripheral effects reduction. Further double - blind randomized studies need to better understand the pilosebaceous unit action mechanism to validate the inositol administration definitively.

Biography :